Actelion's PAH drug meets goals of midstage trial

05/18/2010 | Reuters

Actelion's drug candidate selexipag helped reduce pulmonary vascular resistance by 30.3% in patients with pulmonary arterial hypertension after 17 weeks of treatment during a midstage trial, the company reported. The drug also resulted in "an encouraging numerical improvement" in six-minute walk distance for the patients, who have limited exercise capacity because of the disease.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC